FibroGen

"FibroGen is a research-based biotechnology company using its expertise in connective tissue growth factor (CTGF) and hypoxia-inducible factor (HIF) biology to discover, develop, and commercialize novel therapeutics for serious unmet medical needs."


 * Thomas B. Neff - Chairman, Founder, Chief Executive Officer

Board
Accessed December 2010:


 * Thomas B. Neff - Chairman, Founder, Chief Executive Officer
 * Thomas F. Kearns, Jr. - Retired Partner, Bear, Stearns & Co., Inc.
 * Kalevi Kurkijärvi - Senior Partner, Chairman and CEO, BioFund Management Fund Ltd.
 * Miguel Madero - Fomento Direccion, Mexico
 * Rory B. Riggs - Managing Member, Balfour LLC; Former President and Director, Biomatrix, Inc.
 * Roberto Pedro Rosenkranz - Chairman and Chief Executive Officer, ROXRO PHARMA, Inc.; Director, Pherin Pharmaceuticals
 * Jorma Routti - Chairman of the Board of Directors, FibroGen Europe, Former Director General of the Directorate of Science, Research and Development of the European Commission
 * James A. Schoeneck - CEO and Director, BrainCells Inc.
 * Julian N. Stern - Counsel to Goodwin Procter, LLP.
 * Toshinari Tamura - Former Representative Director, Executive Vice President and Chief Science Officer of Astellas Pharma, Inc.

Contact
URL: http://www.fibrogen.com/

Related Sourcewatch

 * Stephen Evans-Freke
 * Overbrook Foundation